{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:57Z","timestamp":1788841377412,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"DOI":"10.1093\/ckj\/sfx038","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T11:11:16Z","timestamp":1491995476000},"page":"455-460","source":"Crossref","is-referenced-by-count":49,"title":["Infectious complications of rituximab therapy in renal disease"],"prefix":"10.1093","volume":"10","author":[{"given":"Andrew","family":"Nixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Ogden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Woywodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Dhaygude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"key":"key\n\t\t\t\t20171012104458_sfx038-B1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","year":"2001","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B3","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/rheumatology\/ker018","article-title":"The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation","volume":"50","year":"2011","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","article-title":"Suppression of normal immune responses after treatment with rituximab","volume":"28","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","article-title":"A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections","volume":"97","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2215\/CJN.01600214","article-title":"Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis","volume":"9","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10067-014-2509-2","article-title":"Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab","volume":"33","year":"2014","journal-title":"Clin Rheumatol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B9","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","year":"2011","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B10","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B11","first-page":"461","article-title":"Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease","volume":"10","year":"2017","journal-title":"Clin Kidney J"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","article-title":"Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases","volume":"67","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B13","doi-asserted-by":"crossref","first-page":"e37626","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B14","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/rheumatology\/ket257","article-title":"Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre","volume":"52","year":"2013","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12891-015-0860-3","article-title":"Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab","volume":"17","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B16","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","year":"2011","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B17","doi-asserted-by":"crossref","first-page":"e000034","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the autoImmunity and rituximab registry","volume":"1","year":"2015","journal-title":"RMD Open"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B19","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B20","first-page":"143","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B21","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/rheumatology\/ket445","article-title":"BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis","volume":"53","year":"2014","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1179\/1973947815Y.0000000025","article-title":"Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis","volume":"27","year":"2015","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))","volume":"69","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","year":"2006","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","year":"2011","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B28","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","year":"2012","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry","volume":"62","year":"2010","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000360908","article-title":"Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review","volume":"39","year":"2014","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/tri.12616","article-title":"ABO desensitization affects cellular immunity and infection control after renal transplantation","volume":"28","year":"2015","journal-title":"Transpl Int"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B33","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/TP.0b013e3181fa941b","article-title":"Incidence of infectious complications in highly sensitized renal transplant recipients treated by rituximab: a case-controlled study","volume":"90","year":"2010","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B34","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.2215\/CJN.03710411","article-title":"Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin","volume":"6","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000431336","article-title":"Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab","volume":"41","year":"2015","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B36","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jama.2013.281115","article-title":"FDA: increased HBV reactivation risk with ofatumumab or rituximab","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/hep.27716","article-title":"Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00277-016-2700-4","article-title":"Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab","volume":"95","year":"2016","journal-title":"Ann Hematol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","year":"2010","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B42","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3899\/jrheum.150051","article-title":"Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years","volume":"42","year":"2015","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B43","doi-asserted-by":"crossref","first-page":"e0122171","DOI":"10.1371\/journal.pone.0122171","article-title":"Prophylaxis and treatment of Pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/IAI.03099-14","article-title":"Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia","volume":"83","year":"2015","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kes365","article-title":"The effects of rituximab therapy on released interferon-\u03b3 levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection","volume":"52","year":"2013","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B46","first-page":"1683","article-title":"Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis","volume":"35","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B47","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3109\/10428194.2012.717081","article-title":"Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia","volume":"54","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"38","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B49","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B50","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"The effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in ANCA vasculitis","volume":"69","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","year":"2015","journal-title":"J Autoimmun"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B54","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/br.2016.711","article-title":"Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome","volume":"5","year":"2016","journal-title":"Biomed Rep"},{"key":"key\n\t\t\t\t20171012104458_sfx038-B56","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/10\/4\/455\/19377122\/sfx038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T15:00:56Z","timestamp":1719154856000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ckj\/article\/10\/4\/455\/3926545\/Infectious-complications-of-rituximab-therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":56,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,7,6]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfx038","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,7,6]]}}}